Skip to content
Head to head

Hutchmed (China) vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: HCM · TAK

Updated 10 minutes ago

1-year performance, rebased to 100

HCM -10.3%TAK +56.6%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (90); Takeda Pharmaceutical has done best over the past year (+57%); Takeda Pharmaceutical pays the highest dividend yield.
HCMTAK
Snapshot
Sector----
Last price13.2221.77
Change today-1.71%+1.68%
1-year return-6.8%+57.5%
Market cap$2.31B$69.76B
52-week range9.77 – 16.3313.92 – 22.07
Valuation
P/E (TTM)165.25311.00
P/E percentile, own 5-yr range100th100th
P/B1.831.50
Dividend yield0.00%1.44%
Profitability & growth
EPS (TTM)2.60-0.30
Net profit (TTM)$453.61M$-970.94M
Revenue (TTM)--$4.69T
Provider revenue period date2021-06-292026-09-29
Revenue growth (YoY)+37.3%+6.7%
Gross margin41.6%65.8%
Operating margin-5.7%14.3%
Net margin3.3%0.9%
Free cash flow (TTM)--$433.95B
Provider cash-flow period date2021-06-292026-09-29
Ownership & sentiment
Institutional ownership57.7%51.3%
Insider activity (12mo)8 buy / 0 sell19 buy / 31 sell
Short interest (% of float)0.2%0.1%
Analyst consensus100% buy (2)100% buy (1)
Analyst price target$18 (+38%)$50 (+132%)
StockVane view
StockVane Quant RatingD (29)C (90)
Company
Employees1,79647,029
Founded20001781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.